For the Inventor, By the Inventor

Enter assignee name

Msd K.k.

USPTO Granted Patents = 47

% Expired Patents = 12.8

CIPO Patents = 3

EPO Patents = 51

Forward Citations = 166

Loading Chart...

Loading Chart...

111 inventors (with patents filed for the assignee):

Tsuyoshi Nagase (9 out of 15 patents)

Toshihiro Sakamoto (8 out of 29 patents)

Hidetomo Furuyama (7 out of 14 patents)

4. Makoto Bamba (7 out of 13 patents)

5. Nobuhiko Kawanishi (7 out of 14 patents)

6. Nagaaki Sato (7 out of 19 patents)

7. Satoshi Sunami (6 out of 8 patents)

8. Kenji Niiyama (6 out of 17 patents)

9. Keiji Takahashi (6 out of 16 patents)

10. Mitsuru Ohkubo (6 out of 22 patents)

11. Toshiyuki Takahashi (6 out of 24 patents)

12. Teruyuki Nishimura (6 out of 15 patents)

13. Tomoharu Iino (6 out of 12 patents)

14. Yasuhiro Goto (5 out of 37 patents)

15. Yoshio Ogino (5 out of 21 patents)

Core Competencies:

Heteroaryl Quinazoline Derivatives

Dihydropyrazolopyrimidinone Derivatives

AKT Inhibitors

Combination Cancer Therapy

Aminopyridine Derivatives

Pyridinecarboxamide Derivatives

Benzimidazole Derivatives

Spirochromanone Derivatives

Piperidine Derivatives

Sulfonyl-Substituted Derivatives

Fused Ring Compounds

Therapeutic Compounds

47 patents: Sort by Forward Citations

1. 8846700 - Heteroaryl quinazoline derivatives (2014-09-30),

2. 8791125 - Dihydropyrazolopyrimidinone derivatives (2014-07-29),

3. 8765789 - 2-pyridinecarboxamide derivatives (2014-07-01),

4. 8614221 - Inhibitors of Akt activity (2013-12-24),

5. 8609699 - Oxotetrahydrofuran-2-yl-benzimidazole derivative (2013-12-17),

6. 8592428 - Acetyl pyrrolidinyl indole derivative (2013-11-26),

7. 8575179 - Dihydropyrazolopyrimidinone derivatives (2013-11-05),

8. 8536193 - Inhibitors of AKT activity (2013-09-17),

9. 8524730 - Spirochromanone carboxylic acids (2013-09-03),

10. 8519136 - Aminopyridine derivatives having aurora a selective inhibitory action (2013-08-27),

11. 8507505 - Dihydropyrazolopyrimidinone derivative (2013-08-13),

12. 8492397 - Aminopyridine derivatives having Aurora A selective inhibitory action (2013-07-23),

13. 8481503 - Combination cancer therapy with an AKT inhibitor and other anticancer agents (2013-07-09),

14. 8455477 - Therapeutic compounds (2013-06-04),

15. 8436004 - Bicycloaniline derivative (2013-05-07),

Msd K.K., based in Tokyo, specializes in the development and manufacturing of innovative pharmaceutical solutions, particularly in oncology. The company focuses on a range of advanced compounds, including heteroaryl quinazoline derivatives and dihydropyrazolopyrimidinone derivatives, aimed at inhibiting Akt activity and enhancing combination cancer therapies. With a commitment to addressing complex medical challenges, Msd K.K. leverages its expertise in various therapeutic areas, contributing to the advancement of healthcare solutions in Japan and beyond.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

47 Patents

#824 in Tokyo

#1,775 in Japan

#14,796 in the World

Msd K.k.

Forward Citations = 166

111 inventors:

Tsuyoshi Nagase (9 out of 15 patents)

Toshihiro Sakamoto (8 out of 29 patents)

Hidetomo Furuyama (7 out of 14 patents)

4. Makoto Bamba (7 out of 13 patents)

5. Nobuhiko Kawanishi (7 out of 14 patents)

Please report any incorrect information to [email protected]

Loading…